The Coming Wave of Generic Biologics

June 13, 2014 | Matthew Herper examines the market for generic biotech therapies, which have sometimes been seen as more resistant to generic competition than chemically manufactured drugs. Many of the most successful biologics are due to see their patents expire in the near future, including Rituxan and Neulasta, both of which will be open to generic competition in 2015. Herper looks at the few past cases of biotechs going generic to predict which may be vulnerable to a steep loss of market share. Forbes